PMID- 28970454
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 2226-4787 (Electronic)
IS  - 2226-4787 (Linking)
VI  - 5
IP  - 3
DP  - 2017 Jul 28
TI  - Community Pharmacists' Knowledge Regarding Donepezil Averse Effects and Self-Care 
      Recommendations for Insomnia for Persons with AD.
LID - 10.3390/pharmacy5030042 [doi]
LID - 42
AB  - Alzheimer's disease (AD) impacts millions of individuals worldwide. Since no cure 
      is currently available, acetylcholinesterase inhibitors are symptomatic therapy. 
      This study assessed community pharmacists' knowledge regarding donepezil adverse 
      effects (AEs) and self-care recommendations for insomnia management for persons 
      with AD treated with rivastigmine. This is a cross-sectional, standardized 
      telephone survey of community pharmacists (n = 862) in three study areas: West 
      Virginia, North Dakota/South Dakota, and Southern Oregon/Northern California. 
      Pharmacists' degree, sex, and pharmacists' AD-related knowledge were assessed. 
      In-stock availability of donepezil and rivastigmine formulations was assessed. 
      Analyses were performed using Stata 10.1. Only 31.4% pharmacists were able to 
      name >/=2 donepezil AEs. Only four donepezil AEs were named by at least 13% of 
      pharmacists: nausea (36.1%), dizziness (25.1%), diarrhea (15.0%), and vomiting 
      (13.9%). All other AEs were named by fewer than 7% of respondents. Only 62.9% of 
      pharmacists (n = 542) provided appropriate recommendations: melatonin (40.3%), 
      referral to physician (22.0%), or sleep hygiene (0.6%). Over 12% of pharmacists 
      (n = 107) provided inappropriate recommendations (anticholinergic agent or 
      valerian root) and 21.5% of pharmacists were unable to provide any 
      recommendation. We identified significant gaps in community pharmacists' 
      knowledge regarding donepezil AEs and non-prescription insomnia recommendation 
      needing significant improvement to ensure high-quality AD-related care.
FAU - Marvanova, Marketa
AU  - Marvanova M
AUID- ORCID: 0000-0003-4998-8921
AD  - Department of Pharmacy Practice, School of Pharmacy/College of Health 
      Professions, North Dakota State University, Department 2650, P.O. Box 6050, 
      Fargo, ND 58108-6050, USA. marketa.marvanova@ndsu.edu.
FAU - Henkel, Paul Jacob
AU  - Henkel PJ
AD  - Department of Geographical and Historical Studies, University of Eastern Finland, 
      FI-80101 Joensuu, Finland. suomenpoika@yahoo.com.
LA  - eng
PT  - Journal Article
DEP - 20170728
PL  - Switzerland
TA  - Pharmacy (Basel)
JT  - Pharmacy (Basel, Switzerland)
JID - 101678532
PMC - PMC5622354
OTO - NOTNLM
OT  - Alzheimer's disease
OT  - acetylcholinesterase inhibitor
OT  - anticholinergic agent
OT  - cognitive enhancer
OT  - community pharmacist
OT  - donepezil
OT  - pharmaceutical care
OT  - rivastigmine
COIS- The authors declare no conflict of interest.
EDAT- 2017/10/04 06:00
MHDA- 2017/10/04 06:01
PMCR- 2017/07/28
CRDT- 2017/10/04 06:00
PHST- 2017/07/04 00:00 [received]
PHST- 2017/07/25 00:00 [revised]
PHST- 2017/07/25 00:00 [accepted]
PHST- 2017/10/04 06:00 [entrez]
PHST- 2017/10/04 06:00 [pubmed]
PHST- 2017/10/04 06:01 [medline]
PHST- 2017/07/28 00:00 [pmc-release]
AID - pharmacy5030042 [pii]
AID - pharmacy-05-00042 [pii]
AID - 10.3390/pharmacy5030042 [doi]
PST - epublish
SO  - Pharmacy (Basel). 2017 Jul 28;5(3):42. doi: 10.3390/pharmacy5030042.